ArticleAnnals of surgical treatment and research2026
Comparison of four commercially available adhesion barriers after open thyroid surgery: a prospective observational study.
Article in Annals of surgical treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Postoperative cervical adhesions after thyroidectomy can lead to neck tightness, dysphagia, and cosmetic dissatisfaction, but the clinical benefits of antiadhesion agents remain unclear. This study compared the efficacy and safety of four commercially available antiadhesion agents applied after open thyroid surgery. Methods: This singlecenter prospective observational study at a tertiary care hospital included included patients aged 20-70 years undergoing their first open thyroid surgery with intraoperative application of 1 of 4 agents: MegaShield (MS; L&C Bio Co., Ltd.), MegaDerm (MD; L&C Bio Co., Ltd.), CollaBarrier (CB; Dalim Tissen Co., Ltd.), or ACE COL (AC; Korea BNC Co., Ltd. and IreBio Co., Ltd.). Two units were applied at the tracheal bed and subcutaneous layer at the end of surgery. A 7item adhesion questionnaire and the Vancouver Scar Scale (VSS) were assessed at 2 and 12 weeks postoperatively by an independent evaluator. Adverse events were recorded at each visit. Group differences were analyzed using nonparametric tests. Results: Of 200 enrolled patients, 180 completed followup (MS, 46; MD, 45; CB, 47; and AC, 42). Baseline characteristics were comparable. Adhesion scores increased at 2 weeks and improved by 12 weeks in all groups, with no significant betweengroup differences at any time point. VSS total scores showed a similar pattern, with only a transiently higher pigmentation score at 2 weeks in the MS group; no differences persisted at 12 weeks. Complication rates were low and similar across groups. Conclusion: Four different antiadhesion agents demonstrated comparable shortterm efficacy for adhesionrelated symptoms and scar quality after open thyroid surgery, with no clinically meaningful superiority of any single agent. All products were well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.